Treace Medical Concepts, Inc. (TMCI)
| Market Cap | 807.40M |
| Revenue (ttm) | 57.37M |
| Net Income (ttm) | -4.31M |
| Shares Out | 50.46M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
Ponte Vedra-based company plans to reach the market this week.
Treace Medical Concepts, Inc. has filed to go public with an IPO on the NASDAQ.
About TMCI
Treace Medical Concepts is a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions). We have pioneered our proprietary Lapiplasty 3D Bunion Correction System – a combination of novel instruments, implants and surgical methods designed to improve the inconsistent clinical outcomes of traditional approaches to bunion surgery. Although bunions are deformities typically caused by an unstable joint in the middle of the foot that leads to a three-dimensiona... [Read more...]
| Industry Surgical & Medical Instruments | IPO Date Apr 23, 2021 |
| CEO John T. Treace | Employees 133 |
| Stock Exchange NASDAQ | Ticker Symbol TMCI |
Financial Performance
In 2020, TMCI's revenue was $57.37 million, an increase of 45.54% compared to the previous year's $39.42 million. Losses were -$3.67 million, -14.00% less than in 2019.